After Reaching Milestone, Is AMARANTUS BIOSCIENCE HOLDINGS INC (OTCMKTS:AMBS)’s Short Interest Revealing Something?

June 17, 2018 - By Darrin Black

Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS) Logo

The stock of AMARANTUS BIOSCIENCE HOLDINGS INC (OTCMKTS:AMBS) registered an increase of 3415.38% in short interest. AMBS’s total short interest was 45,700 shares in June as published by FINRA. Its up 3415.38% from 1,300 shares, reported previously. The short interest to AMARANTUS BIOSCIENCE HOLDINGS INC’s float is 0.07%.

The stock increased 8.60% or $0.0037 during the last trading session, reaching $0.0467. About 1.39M shares traded or 40.64% up from the average. Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company has market cap of $3.19 million. The companyÂ’s diagnostic products in development include the lymphocyte proliferation test, a diagnostic blood test for AlzheimerÂ’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. It currently has negative earnings. The Company’s therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of ParkinsonÂ’s disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: